Amantadine (hydrochloride) – 50 g

Brand:
Cayman
CAS:
665-66-7
Storage:
-20
UN-No:
Non-Hazardous - /

Amantadine is an NMDA receptor antagonist with IC50 values of 0.93, 0.82, and 0.47 μM at -70 mV for NR1-1a/NR2A, NR1-1a/NR2B, and NR1-1a/NR2D subunit-containing recombinant receptors, respectively, expressed in HEK293 cells.{42217} It blocks the influenza A M2 proton channel (IC50 = 16 μM for the recombinant channel expressed in Xenopus oocytes) and inhibits cytotoxicity induced by the influenza A strains H1N1 and H3N2 in MDCK cells (EC50s = 34 and 0.84 μM, respectively).{42218} It also improves the survival of mice infected with influenza A when administered 24 hours following viral challenge at a dose of 100 mg/kg per day.{42220} Amantadine (40 mg/kg) decreases dyskinesia induced by L-DOPA (Item No. 13248) in a 6-OHDA hemi-parkinsonian mouse model.{42219} Formulations containing amantadine have been used in the treatment of various strains of influenza A virus infection and in the treatment of parkinsonism and drug-induced extrapyramidal symptoms.  

 

Out of stock

SKU: 21364 - Category:

Description

An NMDAR antagonist (IC50s = 0.93, 0.82, and 0.47 μM at -70 mV for NR1-1a/NR2A, NR1-1a/NR2B, and NR1-1a/NR2D subunit-containing recombinant receptors, respectively, expressed in HEK293 cells); blocks the influenza A M2 proton channel (IC50 = 16 μM for the recombinant channel expressed in Xenopus oocytes) and inhibits cytotoxicity induced by the influenza A strains H1N1 and H3N2 in MDCK cells (EC50s = 34 and 0.84 μM, respectively); improves the survival of mice infected with influenza A when administered 24 hours following viral challenge at a dose of 100 mg/kg per day; decreases L-DOPA-induced dyskinesia in a 6-OHDA hemi-parkinsonian mouse model at 40 mg/kg


Formal name: tricyclo[3.3.1.13,7]decan-1-amine, monohydrochloride

Synonyms:  Adamantylamine|Aminoadamantane|NSC 83653

Molecular weight: 187.7

CAS: 665-66-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Ion Channel Modulation|Blockers||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Influenza||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease